https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22523 Wed 11 Apr 2018 13:47:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:106 Tue 20 Aug 2024 12:05:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:164 Thu 25 Jul 2013 09:09:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12306 2 = 79%). When the four trials by Boldt are excluded, the RR is 0.76 (95% CI 0.62 to 0.93). On average, PRP did not significantly reduce the total volume of RBC transfused (weighted mean difference [WMD] -0.69, 95%CI -1.93 to 0.56 units). Trials provided inadequate data regarding the impact of PRP on morbidity, mortality, and hospital length of stay. Trials were generally small and of poor methodological quality. Authors' conclusions: Although the results suggest that PRP is effective in reducing allogeneic RBC transfusion in adult patients undergoing elective surgery, there was considerable heterogeneity of treatment effects and the trials were of poor methodological quality. The available studies provided inadequate data for firm conclusions to be drawn regarding the impact of PRP on clinically important endpoints.]]> Sat 24 Mar 2018 08:11:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10897 Sat 24 Mar 2018 08:09:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10904 Sat 24 Mar 2018 08:07:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19106 Sat 24 Mar 2018 07:55:58 AEDT ]]>